Myokines: Novel therapeutic targets for diabetic nephropathy

被引：7

作者：

Yang, Ming ^{[1
,2
]}

Luo, Shilu ^{[2
]}

Yang, Jinfei ^{[2
]}

Chen, Wei ^{[2
]}

He, Liyu ^{[2
]}

Liu, Di ^{[2
]}

Zhao, Li ^{[3
]}

Wang, Xi ^{[1
,4
]}

机构：

[1] Cent South Univ, Xiangya Hosp, Dept Nutr, Changsha, Hunan, Peoples R China

[2] Cent South Univ, Xiangya Hosp 2, Dept Nephrol, Changsha, Peoples R China

[3] Kunming Med Univ, Affiliated Hosp 1, Dept Reprod & Genet, Kunming, Peoples R China

[4] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China

来源：

FRONTIERS IN ENDOCRINOLOGY | 2022年 / 13卷

基金：

中国国家自然科学基金;

关键词：

myokines; diabetic nephropathy; muscle; irisin; FGF21; GROWTH-FACTOR; 21; GLOMERULAR-FILTRATION-RATE; ACID-BINDING PROTEIN-3; SKELETAL-MUSCLE; INFLAMMATORY MARKERS; ECCENTRIC EXERCISE; PHYSICAL-ACTIVITY; ENDOCRINE ORGAN; FGF21; IRISIN;

D O I：

10.3389/fendo.2022.1014581

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

With the increasing incidence of diabetic nephropathy (DN), there is an urgent need to find effective DN preventive and therapeutic modalities. It is widely believed that effective exercise is good for health. However, the beneficial role of exercise in kidney disease, especially in DN, and the underlying molecular mechanisms have rarely been reported. Muscle is not only an important motor organ but also an important endocrine organ, secreting a group of proteins called "myokines" into the blood circulation. Circulating myokines then move to various target organs to play different biological roles. In this review, we summarize the currently known myokines and the progress in research relating them to DN and discuss its potential as a therapeutic target for DN.

引用

页数：10

共 50 条

[31] DIABETIC NEPHROPATHY - THERAPEUTIC STRATEGIES
BAHNER, U
GEIGER, H
TESCHNER, M
HEIDLAND, A
MEDIZINISCHE WELT, 1988, 39 (36): : 1032 - 1035
[32] Therapeutic Advances in Diabetic Nephropathy
Sawaf, Hanny
Thomas, George
Taliercio, Jonathan J.
Nakhoul, Georges
Vachharajani, Tushar J.
Mehdi, Ali
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (02)
[33] THERAPEUTIC STRATEGIES IN DIABETIC NEPHROPATHY
IRSIGLER, K
KARL, B
OGRIS, E
NIEREN-UND HOCHDRUCKKRANKHEITEN, 1987, 16 (07) : 303 - 307
[34] Novel therapeutic targets in diabetic macular edema: Beyond VEGF
Urias, Elizabeth A.
Urias, George A.
Monickaraj, Finny
McGuire, Paul
Das, Arup
VISION RESEARCH, 2017, 139 : 221 - 227
[35] Targets to retard the progression of diabetic nephropathy
Cooper, ME
Jandeleit-Dahm, K
Thomas, MC
KIDNEY INTERNATIONAL, 2005, 68 (04) : 1439 - 1445
[36] An Updated Review on Diabetic Nephropathy: Potential Mechanisms, Biomarkers, Therapeutic Targets and Interventional Therapies
Nadendla, Rama Rao
Khairunnisa, K.
Aziz, Namra
Pyne, Chandana
Panigrahy, Uttam Prasad
Wal, Pranay
Kulkarni, Mrunalini Harish
Rasheed, Azhar
CURRENT DIABETES REVIEWS, 2025, 21 (09)
[37] Potential Therapeutic Targets of Rehmannia Formulations on Diabetic Nephropathy: A Comparative Network Pharmacology Analysis
Chan, Kam Wa
Yu, Kam Yan
Yiu, Wai Han
Xue, Rui
Lok, Sarah Wing-Yan
Li, Hongyu
Zou, Yixin
Ma, Jinyuan
Lai, Kar Neng
Tang, Sydney Chi-Wai
FRONTIERS IN PHARMACOLOGY, 2022, 13
[38] A comprehensive review of the novel therapeutic targets for the treatment of diabetic cardiomyopathy
Dhar, Arti
Venkadakrishnan, Jegadheeswari
Roy, Utsa
Vedam, Sahithi
Lalwani, Nikita
Ramos, Kenneth S.
Pandita, Tej K.
Bhat, Audesh
THERAPEUTIC ADVANCES IN CARDIOVASCULAR DISEASE, 2023, 17
[39] A novel candidate therapeutic target for diabetic nephropathy: Gas6
Erek, A.
Ozakpinar, O.
Karaca, Z.
Uras, F.
Uras, A. R.
FEBS JOURNAL, 2011, 278 : 327 - 327
[40] Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?
Lavoz, Carolina
Rayego-Mateos, Sandra
Orejudo, Macarena
Opazo-Rios, Lucas
Marchant, Vanessa
Marquez-Exposito, Laura
Tejera-Munoz, Antonio
Navarro-Gonzalez, Juan F.
Droguett, Alejandra
Ortiz, Alberto
Egido, Jesus
Mezzano, Sergio
Rodrigues-Diez, Raul R.
Ruiz-Ortega, Marta
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (01)

← 1 2 3 4 5 →